Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Deciphera Pharmaceuticals logo — A member of ONO Group

Deciphera Pharmaceuticals

A member of ONO Group

Founded 2003 United States Waltham, United States 526 employees Acquired Total: $3.54B

General Information

Company Name Deciphera Pharmaceuticals
Founded Year 2003
Location United States Waltham, United States
Employees 526
Funding Stage Acquired
Business Model B2B, B2C, D2C
Revenue Model Product Sales, Licensing
Social

BounceWatch is an independent company data service, not affiliated with Deciphera Pharmaceuticals. To contact Deciphera Pharmaceuticals, visit deciphera.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Deciphera Pharmaceuticals compare?

A PDF of Deciphera Pharmaceuticals and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Deciphera Pharmaceuticals soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Deciphera Pharmaceuticals

Deciphera Pharmaceuticals, under the slogan A member of ONO Group, is a noteworthy player in the biopharmaceutical sector, dedicated to innovating crucial cancer treatments. Established in 2003, the company leverages a proprietary switch-control kinase inhibitor platform that capitalizes on extensive kinase biology expertise. This scientific edge aids in the development of a wide array of groundbreaking medicines.

The company recently caught the attention of the investment community with a substantial $2.40B acquisition investment on 01 April 2024, orchestrated by ONO Pharmaceutical. This acquisition signals strong confidence from ONO Pharmaceutical in Deciphera's technology and potential market impact. The lack of a specified headquarters in the available data suggests a strategic integration within the ONO Group's global operations framework. Deciphera's focus on innovative cancer treatment positions it as a promising entity in the competitive biopharmaceutical landscape, appealing to investors eyeing breakthrough healthcare solutions.

Business keywords: biopharmaceutical, cancer treatment, medicines development, switch-control kinase inhibitors, kinase biology, drug discovery, oncology, innovation in medicine, pharmaceutical research, tumor treatment, biotech innovation, kinase inhibitor platform

Services & Products

Design and Development of Kinase Inhibitors
Clinical Trials and Studies
Expanded Access Program
Patient Response Improvement Programs

Target Customers

Patients with Cancer Healthcare Professionals Pharmaceutical Partners Clinical Researchers

Funding Rounds & Investors (10)

View All
Funding Stage Amount Investors Lead Investors Date
Acquisition $2.40B 1
ONO Pharmaceutical
01 Apr 2024
Post-IPO Equity $1.23M 1
Sunesis Advisors
01 Jan 2024
Post-IPO Equity $143.70M -
01 Jan 2023
Post-IPO Equity $150.00M -
01 Apr 2022
Post-IPO Equity $400.00M -
01 Aug 2019
Post-IPO Equity $172.00M -
01 Jun 2018
IPO $128.00M -
01 Dec 2017
Series C $52.00M 5
Redmile Group Viking Global Investors Decipher Capital
Redmile Group, Viking Global Investors +3
01 Jun 2017
Series B $15.00M 2
New Leaf Venture Partners SV Health Investors
New Leaf Venture Partners, SV Health Investors
01 Jan 2016
Series B $75.00M 2
New Leaf Venture Partners SV Health Investors
New Leaf Venture Partners, SV Health Investors
01 Sep 2015

Deciphera Pharmaceuticals Alternatives & Competitors

View All Alternatives
Deciphera Pharmaceuticals vs
KeifeRx
KeifeRx United States

KeifeRx is a biopharmaceutical company finding disease-modifying treatments for neurodegenerative di...

Series A
7 employees
Biopharma, Biotechnology
Deciphera Pharmaceuticals vs
Merck & Co., Inc.
Merck & Co., Inc.

Merck develops and produces medicines, vaccines, biologic therapies and animal health products

IPO
92 employees
Biotechnology, Health Care
Deciphera Pharmaceuticals vs
Blueprint Medicines
Blueprint Medicines United States

Striving to improve and extend patients' lives

Acquired
782 employees
Biotechnology, Health Care
Also compare with: Deciphera Pharmaceuticals vs AlloMek Therapeutics LLC AlloMek Therapeutics LLC View all alternatives

FAQ About Deciphera Pharmaceuticals

A member of ONO Group
Deciphera Pharmaceuticals was founded in 2003.
Deciphera Pharmaceuticals is headquartered in Waltham, United States.
Deciphera Pharmaceuticals has a B2B, B2C and D2C business model. Its revenue comes from Product Sales and Licensing.
Deciphera Pharmaceuticals has approximately 526 employees.
Deciphera Pharmaceuticals has completed 10 funding rounds, raising a total of $3.54B. The latest funding stage is Acquired.
Deciphera Pharmaceuticals offers: Design and Development of Kinase Inhibitors, Clinical Trials and Studies, Expanded Access Program, Patient Response Improvement Programs.
Top alternatives and competitors to Deciphera Pharmaceuticals include KeifeRx, Merck & Co., Inc., Blueprint Medicines, Cascadian Therapeutics, Inc., BeyondSpring. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Deciphera Pharmaceuticals and KeifeRx are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Deciphera Pharmaceuticals, https://bouncewatch.com/company/deciphera-pharmaceuticals, updated 11 March 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout